Navigation Links
Asymmetrex Presents Proposal for ASTM Interlaboratory Evaluation of AlphaSTEM Test™ Technology Towards Establishing A Standard for Counting Therapeutic Stem Cells
Date:5/16/2019

In a FDA-contracted Standard Coordinating Body Workshop held at the National Institute of Standards and Technology in Rockville, Maryland, March 18-19 of this year, Asymmetrex founder and director James L. Sherley, M.D., Ph.D. predicted a sea change in thinking on the feasibility of standards for counting therapeutic adult tissue stem cells. Many of the gathered participants dismissed this idea. Few argued against the importance of having a standard for quantifying the number of stem cells in stem cell treatments, stem cell manufacturing, and drug development. However, many were of the view that establishing a standard was out of the question, because adult tissue stem cell science was not sufficiently mature to support a method for counting its essential principals.

Sherley, one of a few adult tissue stem cell experts in the workshop, argued passionately to the contrary, based on the merits of his company’s AlphaSTEM Test™, the first reported technology for achieving specific and accurate counting of therapeutic adult tissue stem cells in complex tissue cell preparations. Asymmetrex’s participation in the March SCB Workshop led to an invitation from ASTM International staff for the company to present a proposal for an interlaboratory evaluation of its new test at a future ASTM Committee meeting.

The American Society for Testing and Materials International is a 121 year-old organization that was founded and exists to improve and assure the quality of a vast landscape of industrial manufactured products. ASTM accomplishes this service to humanity by developing worldwide consensus standards for industrial testing and industrial materials. Though founded on standards for factory operations and building materials, its purview now extends well beyond to medical procedures and human tissue cell quality.

Interlaboratory evaluations are an important step on the path to standard certification by ASTM. Asymmetrex gave an initial presentation of its tissue stem cell counting standard concept at an ASTM International Committee Meeting in Washington, D.C. in November 2018. An interlaboratory evaluation was recommended at that time. In today’s proposal presentation, the company will present test property data from its three current cell culture contractor sites, Toxikon Corporation in Massachusetts, Drik in Oklahoma, and the MTECH-BAF in Maryland. The contractor data establish the general high quality of the AlphaSTEM Test™ for determinations of several different therapeutic human adult tissue stem cell types. The proposed interlaboratory study will go further to evaluate similar test properties across five to ten different academic and industrial labs all testing the same source of human tissue stem cells.

Based on the excellent intrinsic test properties observed for Asymmetrex’s individual contractors, Sherley is optimistic that the interlaboratory study will be similarly supportive for moving on to the final stages of ASTM standard certification. “We want for stem cell medicine what ASTM wants for all industries that serve humanity: ‘Helping our world work better.’ Establishing a standard for counting therapeutic adult tissue stem cells will help stem cell medicine work better.”

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Read the full story at https://www.prweb.com/releases/asymmetrex_presents_proposal_for_astm_interlaboratory_evaluation_of_alphastem_test_technology_towards_establishing_a_standard_for_counting_therapeutic_stem_cells/prweb16316460.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Asymmetrex Publishes Chapter Explaining the Critical Need for Stem Cell Dosing for Success in Stem Cell Medicine
2. Asymmetrex Suggests a Stemgene Relief from Recent Cancer Woes About CRISPR-Cas9 Gene-Editing Therapies
3. Asymmetrex Proposes “Stemgene Therapy” to Emphasize the Importance of Tissue Stem Cells for Successful Gene Therapy
4. ACEA Presents xCELLigence Research Grant to Dr. Teresa Krabbe
5. Rigaku Presents Latest XRM and CT Technology at 2019 TSM Meeting
6. Ambry Genetics Presents Research on the Importance of Reclassifying Disease-Causing Genes at the National Society of Genetic Counselors (NSGC) Annual Meeting
7. Horizon Discovery Presents an Educational Webinar on CRISPR-Cas9 Genome Engineering in Primary T cells
8. The 5th Annual Mobile in Clinical Trials Event Presents Agenda for September 24, 2018
9. DERMALOG Presents the Worlds First Combined Fingerprint and Passport Scanner
10. Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020
11. NXT-ID, Inc.s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2019)... , ... May 24, 2019 , ... Zolgensma (Novartis, AveXis), ... AVXS-101, was approved for clinical use in the United States by the Food and ... gene therapy approved to treat inherited genetic disorders in the United States and the ...
(Date:5/23/2019)... ... May 23, 2019 , ... Federal Publications Seminars, the leading provider of government ... the release of FPSOnline 2.0, an updated version of its FPSOnline platform. ... La Jolla Government Contracts Week, were given a “sneak peek” of FPSOnline 2.0 during ...
(Date:5/23/2019)... ... May 23, 2019 , ... ... sales and service organizations, today announced its inclusion in DMG Consulting’s 2019-2020 Intelligent ... intelligent virtual agent (IVA) market share leader, based on number of customers, with ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... BOSTON (PRWEB) , ... May 30, 2019 , ... ... Current regulatory thinking on Data Integrity on July 08-09, 2019 in Boston, MA. ... pharmaceutical, biotech and medical device organizations. , The training will kick off with ...
(Date:5/22/2019)... ... 22, 2019 , ... Artemis (formerly Agrilyst), the leading enterprise Cultivation ... round co-led by Astanor Ventures and Talis Capital with participation ... iSelect Fund . The company has raised $11.75m to date and will use the ...
(Date:5/15/2019)... ... May 16, 2019 , ... Emulsifiers are the magic bullet ... products rely on these ingredients to create stable quality food that can withstand ... shift triggers food formulators to seek out alternatives for starches, gums and chemical ...
(Date:5/8/2019)... ... May 07, 2019 , ... Standing at 16.2 hands, Atlas is on the large side ... drill team and barrel racing, among other activities. When loping around a corner in ... from being a busy horse to only being able to walk. Fortunately Atlas’ owner, ...
Breaking Biology Technology: